US7027121000 - Common Stock
PASSAGE BIO INC
NASDAQ:PASG (12/6/2024, 8:06:29 PM)
After market: 0.813 +0.04 (+4.9%)0.775
+0.07 (+9.15%)
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 58 full-time employees. The company went IPO on 2020-02-28. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
PASSAGE BIO INC
One Commerce Square, 2005 Market Street, 39Th Floor
PHILADELPHIA PENNSYLVANIA 19103
P: 12678660312
CEO: Bruce Goldsmith
Employees: 58
Website: https://www.passagebio.com/
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
These stocks are moving in today's session
Which stocks are moving after the closing bell on Thursday?
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data...
Here you can normally see the latest stock twits on PASG, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: